EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Allogeneic natural killer cell therapy

Melissa M Berrien-Elliott iD, Miriam T Jacobs iD, Todd A Fehniger iD

Blood · 23.02.2023 · 141 (8) · 856-868

DOI: 10.1182/blood.2022016200 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, erschienen am 23.02.2023. Verfasst von Melissa M Berrien-Elliott und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Neoplasms, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 235-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interest in adoptive cell therapy for treating cancer is exploding owing to early clinical successes of autologous chimeric antigen receptor (CAR) T lymphocyte therapy. However, limitations using T cells and autologous cell products are apparent as they (1) take weeks to generate, (2) utilize a 1:1 donor-to-patient model, (3) are expensive, and (4) are prone to heterogeneity and manufacturing failures. CAR T cells are also associated with significant toxicities, including cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, and prolonged cytopenias. To overcome these issues, natural killer (NK) cells are being explored as an alternative cell source for allogeneic cell therapies. NK cells have an inherent ability to recognize cancers, mediate immune functions of killing and communication, and do not induce graft-versus-host disease, cytokine release syndrome, or immune effector cell–associated neurotoxicity syndrome. NK cells can be obtained from blood or cord blood or be derived from hematopoietic stem and progenitor cells or induced pluripotent stem cells, and can be expanded and cryopreserved for off-the-shelf availability. The first wave of point-of-care NK cell therapies led to the current allogeneic NK cell products being investigated in clinical trials with promising preliminary results. Basic advances in NK cell biology and cellular engineering have led to new translational strategies to block inhibition, enhance and broaden target cell recognition, optimize functional persistence, and provide stealth from patients’ immunity. This review details NK cell biology, as well as NK cell product manufacturing, engineering, and combination therapies explored in the clinic leading to the next generation of potent, off-the-shelf cellular therapies for blood cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveCytokine Release SyndromeKiller Cells, NaturalNeurotoxicity Syndromes

Substanzen

cell-associated neurotoxicity

Autor:innen und Institutionen

  • Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.

ORCID-Profile: Melissa M Berrien-Elliott, Miriam T Jacobs, Todd A Fehniger

Förderung

  • NCI NIH HHS

Zitieren

APA

Berrien-Elliott, M. M., Jacobs, M. T., & Fehniger, T. A. (2023). Allogeneic natural killer cell therapy. Blood, 141(8), 856-868. https://doi.org/10.1182/blood.2022016200

Vancouver

Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141(8):856-868. doi:10.1182/blood.2022016200

BibTeX
@article{BerrienElliott2023,
  author = {Berrien-Elliott, Melissa M and Jacobs, Miriam T and Fehniger, Todd A},
  title = {Allogeneic natural killer cell therapy},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {8},
  pages = {856--868},
  doi = {10.1182/blood.2022016200}
}
Kostenlos starten →